- ►diabetesjournals.org DJ Drucker - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide
(GIP) exert important effects on β-cells to stimulate glucose-dependent insulin secretion. Both
peptides also regulate β-cell proliferation and cytoprotection. GLP-1, but not GIP, inhibits ... Cited by 284 - Related articles - All 13 versions
- ►endojournals.org OG Kolterman, JB Buse, MS Fineman, E Gaines … - Journal of Clinical …, 2003 - Endocrine Soc Despite the advent of new treatments, glucose control in the type 2 diabetes population is
unsatisfactory. AC2993 (synthetic exendin-4; exenatide), a novel glucose-dependent insulinotropic
agent, exhibited notable antidiabetic potential in two clinical studies in patients with type 2 ... Cited by 277 - Related articles - BL Direct - All 6 versions
- ►glucagon.com [PDF] DJ Drucker - Gastroenterology, 2002 - Elsevier The glucagon-like peptides (GLP-1 and GLP-2) are proglucagon-derived peptides cosecreted
from gut endocrine cells in response to nutrient ingestion. GLP-1 acts as an incretin to lower
blood glucose via stimulation of insulin secretion from islet (β cells. GLP-1 also exerts ... Cited by 252 - Related articles - BL Direct - All 13 versions
Y Li, T Hansotia, B Yusta, F Ris, PA Halban, DJ … - Journal of Biological …, 2003 - ASBMB Glucagon-like peptide-1 (GLP-1) stimulates insulin secretion and augments β cell mass via activation
of β cell proliferation and islet neogenesis. We examined whether GLP-1 receptor signaling modifies
the cellular susceptibility to apoptosis. Mice administered streptozotocin (STZ), an agent ... Cited by 254 - Related articles - BL Direct - All 7 versions
- ►diabetesjournals.org MS Fineman, TA Bicsak, LZ Shen, K Taylor, E … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—All three AC2993 regimens led to significant reductions in serum fructosamine relative
to placebo (P ≤ 0.004). Mean reductions ranged from 39 to 46 μmol/l. All AC2993 groups had
reductions in HbA 1c ranging from 0.7 to 1.1% (P ≤ 0.006). An end-of-study HbA 1c <7% ... Cited by 231 - Related articles - BL Direct - All 10 versions
- ►endojournals.org DJ Drucker - Molecular Endocrinology, 2003 - Endocrine Soc Peptide hormones are secreted from endocrine cells and neurons and exert their actions through
activation of G protein-coupled receptors to regulate a diverse number of physiological systems
including control of energy homeostasis, gastrointestinal motility, neuroendocrine circuits, ... Cited by 228 - Related articles - BL Direct - All 8 versions
- ►endojournals.org PL Brubaker, DJ Drucker - Endocrinology, 2004 - Endocrine Soc Gut peptides exert diverse effects regulating satiety, gastrointestinal motility and acid
secretion, epithelial integrity, and both nutrient absorption and disposal. These actions are initiated
by activation of specific G protein-coupled receptors and may be mediated by direct or ... Cited by 217 - Related articles - BL Direct - All 7 versions
- ►endojournals.org L Farilla, A Bulotta, B Hirshberg, S Li Calzi, N Khoury, H … - Endocrinology, 2003 - Endocrine Soc The peptide hormone, glucagon-like peptide 1 (GLP-1), has been shown to increase
glucose-dependent insulin secretion, enhance insulin gene transcription, expand islet cell
mass, and inhibit ß-cell apoptosis in animal models of diabetes. The aim of the present ... Cited by 218 - Related articles - BL Direct - All 5 versions
LL Nielsen, AA Young, DG Parkes - Regulatory peptides, 2004 - Elsevier Exenatide (synthetic exendin-4), glucagon-like peptide-1 (GLP-1), and GLP-1 analogues have
actions with the potential to significantly improve glycemic control in patients with diabetes. Evidence
suggests that these agents use a combination of mechanisms which may include glucose- ... Cited by 185 - Related articles - All 7 versions
L Blonde, EJ Klein, J Han, B Zhang, SM Mac, … - Diabetes, Obesity & …, 2006 - pt.wkhealth.com Results: Patients completed 82 weeks of exenatide treatment [n = 314, 63% M, age 56 ± 10
years, weight 99 ± 21 kg, body mass index 34 ± 6 kg/m 2 , A1C 8.3 ± 1.0% (mean ± SD)]. Reduction
in A1C from baseline to week 30 [-0.9 ± 0.1% (mean ± SE)] was sustained to week 82 ... Cited by 174 - Related articles - BL Direct - All 6 versions
